Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMI-137 molecular fluorescence endoscopy feasibility study in Barrett's esophagus
NL-OMON42946Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Oct 2017
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Open-label, single-arm trial of emi-137 in Barrett's esophagus and esophageal adenocarcinoma (EAC), sponsored by University Medical Center Groningen. Primary endpoints: Safety of EMI-137 molecular fluorescence endoscopy and Feasibility of detecting dysplastic or malignant lesions with EMI-137. Started Oct 2017; status: active, not recruiting.
02
Drugs
emi-137
03
Conditions
Barrett's esophagusesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NL-OMON42946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42946.